Articles tagged with Neuralgia
This study examines the effectiveness of combining microvascular decompression with nerve combing for patients with atypical trigeminal neuralgia, a chronic pain condition that does not respond well to conventional treatments. The procedure has shown promising results in reducing pain levels and improving patient outcomes.
A team of researchers, funded by ARPA-H, aims to create an objective quantitative tool to assess pain in patients. They will use biomarkers such as stress hormones and neurotransmitters to generate a composite panel of markers that can be monitored on a portable device.
A case report describes the successful use of thoracic paravertebral blocking to manage severe chronic pain associated with post-herpetic neuralgia. The procedure, involving repeated injections of levobupivacaine and dexamethasone, resulted in significant pain subsidence and reduced medication needs.
A real-world study published in Pain Practice found that patients with neuropathic back pain, postoperative/posttraumatic pain, or shingles experienced reduced pain intensity after multiple high-concentration capsaicin patch applications. The study also showed a significant reduction in opioid use among participants.
A recent study found that transient inflammatory pain causes persistent mitochondrial and metabolic disturbances in sensory neurons, leading to failure in pain resolution. Targeting the cellular redox balance prevents and treats chronic inflammatory pain in rodents.
Trigeminal nerve and hippocampus volumes predict successful surgical treatment outcomes, with non-responders showing larger intracranial volume and contralateral hippocampus volume. The study suggests that neuroanatomical features may be key to understanding chronic pain resistance.
Researchers discovered the role of cytokine TNF in causing herpetic neuralgia, a common symptom of shingles. The study provides insights into novel therapeutic approaches to combat acute and chronic pain associated with the condition.
Researchers have discovered a novel substance that may effectively treat trigeminal neuralgia, a chronic nerve pain condition. The substance, BIIB074, inhibits the sodium channel 1.7, reducing pain intensity without burdening side effects.
Percutaneous stereotaxic rhizotomy (PSR) provides good pain relief at a much lower cost than other surgical treatments, but is underutilized due to limited data and complications. The study found PSR to be eight times more cost-effective than microvascular decompression and 13 times more cost-effective than stereotactic radiosurgery.
A study by Beaumont Health System found Gamma Knife treatment provides acceptable relief for those with severe facial pain caused by TN. Patients treated with Gamma Knife Stereotactic Radiosurgery reported reduced discomfort and resumed daily activities without pain.
A study found that the shingles vaccine halves the occurrence of this painful skin and nerve infection in people over 65. However, vaccination rates are low in the US, particularly among black people and those with low incomes.
A recent study led by academics from the University of Bristol's School of Veterinary Sciences found that caudal compression of the infraorbital nerve can be a viable option for headshaking in horses. The procedure showed a nearly 50% long-term success rate, offering a promising alternative to euthanasia.
Researchers treated 17 patients with trigeminal neuralgia using Cyberknife radiosurgery, resulting in partial or complete relief from symptoms for 14 patients. The procedure offered a viable alternative to invasive approaches, with no major complications reported.
Stereotactic radiation is a proven alternative to surgery or anti-epileptic drugs for treating trigeminal neuralgia in MS patients. The study shows that radiosurgery using Gamma Knife is highly effective in reducing pain and improving quality of life for those affected.
A new guideline developed by the American Academy of Neurology recommends surgery as a treatment option for people with extreme face pain due to trigeminal neuralgia. The guideline suggests that patients who don't respond well to drugs should consider surgical interventions to target the root of the trigeminal nerve.
A small study found that antiviral therapy with acyclovir and valacyclovir can significantly reduce postherpetic neuralgia symptoms in patients with moderate to severe nerve pain following shingles. Eight out of 15 participants reported a significant reduction in pain after one month of treatment.
A new procedure-based consent form developed by surgeons at the University of Pittsburgh Medical Center significantly improves patient recall of diagnoses, procedures, and treatment alternatives. The study found that 98% of patients recalled treatment alternatives and 97% recalled risks after using the specialized form.
Researchers found botulinum toxin type A significantly reduced pain in all 13 patients with trigeminal neuralgia within 10 days of injection. By 60 days, four patients became medication-free and others reduced their medication use by over 50%.
The Gamma Knife treatment has been shown to provide significant pain relief and quality of life improvements for over 90% of patients with trigeminal neuralgia. Facial numbness was a common side effect, but its impact on daily life was often less severe than the debilitating pain it replaced.
The company will use the investment to accelerate its drug development program for neuropathic pain, a prevalent condition affecting an estimated 45% of diabetics and 75% of those over 70. With a significant worldwide market valued at US$3 billion, Spinifex aims to deliver a novel solution to this unmet medical need.
The study highlights the need for personalized treatment approaches in postherpetic neuralgia. A quantitative systematic review of analgesic therapy found that treatments only worked in selected patients, suggesting a range of underlying mechanisms causing pain in different individuals.
A stronger version of the chickenpox vaccine has been shown to prevent shingles in older adults, reducing incidence by 51% and total burden of pain by 61%. The vaccine also significantly reduces postherpetic neuralgia, a debilitating form of chronic nerve pain.
The new guideline suggests tricyclic antidepressants, gabapentin, lidocaine skin patch, and opioids as effective in reducing pain from postherpetic neuralgia. However, the long-term effects of these treatments are not yet supported by sufficient data.
A single application of high-concentration capsaicin patches has been shown to provide significant long-term pain relief for patients with postherpetic neuralgia, a condition that often persists for years. The patch-based treatment avoids systemic side effects associated with traditional treatments.
Researchers from Johns Hopkins University and National Institutes of Health found opioids to be highly effective in reducing pain in PHN patients, while causing no appreciable cognitive decline. The study's results provide convincing evidence for the use of opioids as an alternative treatment option for neuropathic pain.